SEC filingsOct 12, 2026 to Oct 19, 2026: insiders reported 840 purchases and sales across 212 companies.840 insider purchases and sales in 7 daysSee the filings →
HornScout

Company profile

OVID

Ovid Therapeutics Inc.
NASDAQHealth Care

Latest close: 2.15 USD · Oct 16, 2026 · 1 year · split-adjusted

On the price, the facts of the public record■Insider buy□Insider sell●Results filed
With an account, also○dividends▲splits◌next earningswith an account

End-of-day prices provided by Twelve Data · One close per session; the series does not update during the trading day.

Latest on record

The most recent facts, as filed.

Up to three of the most recent, checkable facts already loaded on this page, each linked to its source.

  1. Aug 24, 2026Notice of sale · Form 144Jeffrey A. Rona · Affiliated Stockholder · $910.0KOpen the filing ↗
  2. Aug 14, 2026Notice of sale · Form 144Jeffrey A. Rona · Affiliated Stockholder · $420.0KOpen the filing ↗
  3. Aug 13, 2026Quarterly report · 10-QFiled by the company itself.Open the filing ↗

In numbers

What this profile holds, counted.

Closes · 1 year250
SEC filings on record50119 flagged findings
Reported transactions (Form 4)62since Sep 20, 2019 · and 12 other holdings
Corporate events (8-K)30since May 15, 2019

What the record says

Description, identity and filings, each with its source.

Every block cites its source. The colour of a finding marks its category — which document, who filed it — not how much it matters.

SEC topics

Regulatory history

Topics detected in its SEC reports, with the original excerpt.

Each topic is assigned by a classifier over the full filing; the excerpts show where it was detected and are not always enough to verify it. Open the filing to read it in full.

  • 2026-05-12share offering or dilution eventrecentOpen filing ↗
    “…2023, the Company filed a shelf registration statement on Form S-3 (Registration No. 333-275307) that allows us to sell up to an…”
    +1 more passage from the same document
    • “…Warrants ( 2,856,666 ) 2,856,666 0.001 6,339 Outstanding, March 31, 2026 48,344,996 13,558,376 $ 1.09 $ 68,067 At-the-Market…”
  • 2026-05-12capital return (buybacks/dividends)recentOpen filing ↗
    “…basis point change in interest rates would not have a material effect on the fair market value of our cash equivalents and…”
  • 2026-05-12Department of Justice inquiryrecentOpen filing ↗
    “…particularly to the United States, are subject to increased scrutiny from regulators, individual litigants, and activist…”
  • 2026-04-27share offering or dilution eventrecentOpen filing ↗
    “…of common stock, consisting of (i) 19,154,321 shares of our common stock and (ii) Pre-Funded Warrants to purchase up to…”
    +1 more passage from the same document
    • “…common stock and (ii) Pre-Funded Warrants to purchase up to 10,701,710 shares of our common stock to the Investors in a private…”

Original excerpts from SEC filings, untranslated. Not advice and not a prediction.

SEC record

SEC dossier

What this company has filed with the SEC, in plain language.

The 25 most recent filings (of 501)

Everything filed

Every SEC filing, newest first, with what it is. Below, each type with its own explanation.

  • Aug 24, 26Form 144 ↗Notice of proposed sale
  • Aug 14, 26SCHEDULE 13G/A ↗Passive stake · Eventide Asset Management, LLC · 6.3% · event on Jun 30, 26 · amendment
  • Aug 14, 26Form 144 ↗Notice of proposed sale
  • Aug 14, 26SCHEDULE 13G/A ↗Passive stake · RA Capital Management, L.P. · 9.9% · event on Jun 30, 26 · amendment
  • Aug 14, 26SCHEDULE 13G/A ↗Passive stake · BALYASNY ASSET MANAGEMENT L.P. · 5.0% · event on Jun 30, 26 · amendment
  • Aug 14, 26SCHEDULE 13G/A ↗Passive stake · ADAR1 Capital Management, LLC · 5.1% · event on Jun 30, 26 · amendment
  • Aug 13, 2610-Q ↗Quarterly report
  • Aug 13, 268-K ↗Current report · Financial statements and exhibits
  • Aug 13, 26SCHEDULE 13G/A ↗Passive stake · Affinity Asset Advisors, LLC · 7.9% · event on Jun 30, 26 · amendment
  • Jul 29, 26SCHEDULE 13G ↗Passive stake · BlackRock, Inc. · 5.8% · event on Jun 30, 26
  • Jul 8, 26Form 4 ↗Insider transaction
  • Jul 8, 26Form 3 ↗Insider transaction
  • Jul 8, 268-K ↗Current report · A senior executive left or was appointed
  • Jul 8, 26SCHEDULE 13G/A ↗Passive stake · Federated Hermes, Inc. · 4.2% · event on Jun 30, 26 · amendment
  • Jun 17, 26Form 4 ↗Insider transaction
  • Jun 17, 26Form 3 ↗Insider transaction
  • Jun 11, 268-K ↗Current report · Shareholder vote results
  • Jun 3, 268-K ↗Current report · A senior executive left or was appointed
  • May 15, 26SCHEDULE 13G ↗Passive stake · Eventide Asset Management, LLC · 7.3% · event on Mar 31, 26
  • May 15, 26SCHEDULE 13G ↗Passive stake · Balyasny Asset Management L.P. · 5.3% · event on Mar 31, 26
  • May 15, 26SCHEDULE 13G/A ↗Passive stake · Point72 Asset Management, L.P. · 1.3% · event on Mar 31, 26 · amendment
  • May 15, 26SCHEDULE 13G ↗Passive stake · Sirenia Capital Management LP · 9.9% · event on Mar 31, 26
  • May 14, 26SCHEDULE 13G/A ↗Passive stake · Jeremy M. Levin · 4.5% · event on Mar 31, 26 · amendment
  • May 14, 26SCHEDULE 13G/A ↗Passive stake · Affinity Asset Advisors, LLC · 9.1% · event on Mar 31, 26 · amendment
  • May 12, 2610-Q ↗Quarterly report

501 filings on record, the oldest from Mar 6, 17.

Listing the 25 most recent filings of the 501 on record.

8-Ks, explained

Stress2Structure14Governance20
  • Jul 8, 26GovernanceA senior executive left or was appointed8-K 5.02 ↗
  • Jun 3, 26GovernanceA senior executive left or was appointed8-K 5.02 ↗
  • Mar 18, 26StructureEntered a material agreement+3 more in the same filing8-K 1.01 ↗
  • Nov 12, 25GovernanceA senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
  • Oct 3, 25StructureEntered a material agreement+4 more in the same filing8-K 1.01 ↗
  • Mar 5, 25GovernanceA senior executive left or was appointed8-K 5.02 ↗
  • Feb 13, 25StressListing notice (8-K 3.01)8-K 3.01 ↗
  • Sep 11, 24GovernanceA senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
  • Aug 2, 24GovernanceA senior executive left or was appointed8-K 5.02 ↗
  • Jun 28, 24StressRestructuring plan with committed costs+2 more in the same filing8-K 2.05 ↗
  • Oct 18, 23StructureEntered a material agreement+3 more in the same filing8-K 1.01 ↗
  • Jan 3, 22StructureEntered a material agreement+3 more in the same filing8-K 1.01 ↗

13 older filings not shown · The record reaches back to Jun 15, 17.

Corporate events are tracked from 2004-08-23, when the SEC renumbered 8-K items. Earlier filings use an incompatible numbering and are not classified here.

Ownership and control

Schedule 13G: short-form filing

The short form, for holders who meet specific requirements: institutional investors, passive investors without a control purpose, or exempt investors. Asset managers and index funds usually file it.

  • RA Capital Management, L.P.9.9%Jun 30, 26SCHEDULE 13G/A ↗4 co-filers on this document — the figure is the largest single stake, not their sum.
  • Sirenia Capital Management LP9.9%Mar 31, 26SCHEDULE 13G ↗2 co-filers on this document — the figure is the largest single stake, not their sum.
  • Affinity Asset Advisors, LLC7.9%Jun 30, 26SCHEDULE 13G/A ↗2 co-filers on this document — the figure is the largest single stake, not their sum. · 2 earlier filings
  • Eventide Asset Management, LLC6.3%Jun 30, 26SCHEDULE 13G/A ↗3 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing
  • BlackRock, Inc.5.8%Jun 30, 26SCHEDULE 13G ↗
show 5 more holdershide
  • ADAR1 Capital Management, LLC5.1%Jun 30, 26SCHEDULE 13G/A ↗3 co-filers on this document — the figure is the largest single stake, not their sum.
  • BALYASNY ASSET MANAGEMENT L.P.5.0%Jun 30, 26SCHEDULE 13G/A ↗5 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing
  • Jeremy M. Levin4.5%Mar 31, 26SCHEDULE 13G/A ↗
  • Federated Hermes, Inc.4.2%Jun 30, 26SCHEDULE 13G/A ↗5 co-filers on this document — the figure is the largest single stake, not their sum.
  • Point72 Asset Management, L.P.1.3%Mar 31, 26SCHEDULE 13G/A ↗3 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing

Structured 13D/G data starts 2023-12, when the SEC moved these filings to a machine-readable format. Earlier filings exist but are not parsed here.

Sale intention announced

On Aug 24, Jeffrey A. Rona filed notice of intent to sell up to $910K. That is about 0.17% of shares outstanding.

A notice is not a sale: it may not go ahead, may happen in part, or at a different price.

No sale of theirs is on record yet in Form 4; the 90-day window is still open.

View notice (Form 144) ↗+1 more recent notices

SEC record

Insider transactions

Buys and sells reported by officers, directors and major shareholders on SEC Form 4.

Buys and sells

  • Feb 23, 26Sell$12KJeffrey A RonaCBFO↗
  • Feb 23, 26Sell$17KMARGARET A. ALEXANDERPresident and CEO↗
  • Feb 26, 25Sell$2KJeffrey A RonaCBFO↗
  • Feb 26, 25Sell$3KMARGARET A. ALEXANDERPresident and COO↗
  • Jan 27, 25Buy$5KMARGARET A. ALEXANDERPresident and COO↗
  • Mar 18, 24Buy$50KJEREMY M LEVINCEO↗
Stock compensation, tax and giftsshow the 16 other transactionshide

Stock compensation, tax withholding, option exercises and gifts. They are listed separately and are not included in the purchase and sale totals. The type describes the transaction, not the filer's intent.

  • Jul 6, 26Compensationamount n/aCharles Ross CarterChief Financial Officer↗
  • Apr 7, 26Compensation$45KSTELIOS PAPADOPOULOS↗
  • Apr 7, 26Compensation$22KBart Friedman↗
  • Apr 7, 26Compensation$45KKevin Joseph Fitzgerald↗
  • Mar 23, 26Compensation$66KJEREMY M LEVINExecutive Chairman↗
  • Feb 26, 26Compensationamount n/aJeffrey A RonaCBFO↗
  • Dec 15, 25Otheramount n/aJEREMY M LEVINCEO↗
  • Dec 8, 25Otheramount n/aTAKEDA PHARMACEUTICAL CO LTD↗
  • Feb 20, 25Compensationamount n/aMARGARET A. ALEXANDERPresident and COO↗
  • Feb 20, 25Compensationamount n/aJeffrey A RonaCBFO↗
  • Feb 22, 24Compensationamount n/aThomas Michael PeroneGeneral Counsel, Secretary↗
  • Feb 22, 24Compensationamount n/aJeffrey A RonaCBFO↗
  • Feb 22, 24Compensationamount n/aJason TardioChief Operating Officer↗
  • Dec 4, 23Giftamount n/aJEREMY M LEVINCEO↗
  • Dec 4, 23Giftamount n/aJEREMY M LEVINCEO↗
  • Sep 20, 19Giftamount n/aJEREMY M LEVINCEO↗

The full record holds 22 transactions and goes back to Sep 20, 19.

Its sector and its market

Ovid Therapeutics Inc. among Health Care companies

The profile shows what is on record. Context and Radar place the company among those of its sector and region.

With an account you also get

  • The four engines — growth, trend, risk and context — each with its word and its score.
  • The risk band and the sector phase.
  • The company's fundamentals and accounts.
  • Watchlist: your list of companies, with the «since you follow it» figure.

The research continues

The profile tells the story. The market sets the scene.

From Ovid Therapeutics Inc., the path continues in the other areas. Each one is shown with its own example, named in its step.

  1. Place it in its market

    Seven layers of its region's market — rates, credit, stress, liquidity, regime, breadth and sectors — with historical precedents. Public example: Apple and ASML.

    See how Context works →
  2. See what deserves a closer look

    Every morning Radar screens the covered companies through a lens and explains why each candidate made the list. Public example: the lists from Aug 11, 2026.

    See how Radar works →
  3. Keep the why

    Follow Ovid Therapeutics Inc. in the Watchlist and review what changed since you added it: context, notices and filings. Written theses are coming soon. Public example: Apple.

    See an example review →

Coverage

What sits behind this page.

Where each figure comes from and how far it reaches.

Prices
End-of-day closes provided by Twelve Data. One close per session; not real time. Closes adjusted for splits.
Series quality
250 clean closes in the period.
SEC records
501 documents on file, from Mar 6, 2017 to Aug 24, 2026.
Company description
No description available.
This page
Generated on Oct 19, 2026; refreshed through the day.

Start at your own pace

Explore first. Go deeper with access.

Every company's public profile is open. The full reading — context, Radar, watchlist — is inside, in an invitation-only beta.

Compare plans →
  • No account

    This profile for every company we cover: closing prices with the record's facts on the curve, the SEC file in plain language, insider trades included, and links to its sector and exchange.

  • Pro

    What matters today, with its reason, is free with an account. Pro adds, in the profile, each company's notices and their explanation and the analysis of its insiders; in Radar, all the lenses, which notice each candidate carries, filters by notice type and «no dilution», and the cycle cohort filter; and in Watchlist, more companies and notice changes with their reason.

  • Pro+

    Adds the Lab: test a hypothesis on comparable cohorts before reusing it; and bring your lenses to Radar.

Are the prices real time?

No. It is one close per session, from the provider and with the date shown on the profile; it does not update during the trading day.

Which SEC documents appear here?

Those filed with the SEC by the company, its insiders and its major shareholders, within our coverage: periodic reports (10-K, 10-Q, 20-F), material events (8-K), proposed sale notices (Form 144), insider transactions (Form 4) and stakes above 5% (13D/13G). Each links to the original on EDGAR.

Why does a European company show no SEC records?

It depends on the company: some European issuers file a 20-F or 6-K with the SEC and others don't. The profile shows whatever is on record; when there is nothing, it says so rather than guessing why. Europe does not yet have a common filing archive like EDGAR in the United States. The EU will open its own, ESAP, in July 2027 (managers' transactions arrive in January 2028), and we plan to add it once it is available.

Before forming a view on a company,
read what is on record.

One close per session. The record in plain language. Its sector and its market one link away. Your judgment when deciding.

Access by invitation while the beta lasts. Not advice: the profile shows what is on record; it does not recommend.